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To the Editor: 
 
We read the article from Pol [1] with great interest, as it provides data that 
support the notion that patients with a history of treated hepatocellular 
carcinoma (HCC) do not have an increased risk for recurrence when treated 
with direct-acting antivirals (DAAs). This article follows the investigations from 
Reig et al. and Buonfiglioli et al., who reported an unexpected early HCC 
recurrence in patients treated with DAAs [2, 3]. Reig et al. noted this trend to 
be increased when the DAA treatment was taken in the 4 months following 
HCC treatment, which makes this particular time frame of most interest. 
These analyses have limitations as acknowledged by the authors themselves 
and as reported by others [4, 5]. Among these are the small number of 
patients and the absence of comparison arms. However, it was important to 
publish these findings to alert other centers to investigate this issue. 
 
In the current state of knowledge, this important issue remains unclear and 
well-designed studies with proper comparison arms are required to determine 
the effect of DAAs on HCC recurrence. For this purpose, Pol used three 
French cohorts to investigate the effect of DAAs on HCC recurrence. The 
HEPATHER cohort provided the opportunity to study a significantly larger 
group of patients who were HCV-infected with a history of treated HCC 
(n=267) than previously published; of whom, 189 had been treated with a 
DAA. The author found no difference in HCC recurrence rates between 
treated and untreated patients with DAAs. In our opinion, some points merit 
further comment.   
 
Almost two-thirds of the cohort were diagnosed with HCC more than 1 year 
before inclusion in the cohort (65.5% [n=175] >1 year; 34.8% [n=93] 
>3 years). As the analysis only began at the time of inclusion in the cohort, 
the study misses – for most of the patients – the particular time frame, 
identified by Reig et al., at which patients seem to be at risk for HCC 
recurrence. This may lead to potential underestimation of recurrences in the 
treated group. Furthermore, it has the potential to lower the rate of HCC 
recurrence by ignoring patients who had HCC recurrence and died before 
inclusion, since these patients were specifically excluded from the cohort.  
 
  
In the survival analysis (Figure 1 of the article), it seems that the whole cohort 
is included in the untreated group, and that patients were censored as they 
received DAA treatment. This methodology may artificially decrease the rate 
of HCC recurrence that arises in patients not receiving DAA therapy.  
 
Finally, the information given about the radiological assessment of the liver is 
limited. It would be very interesting to know what the delay was between the 
last radiological assessment and the beginning of DAA treatment. 
 
We congratulate Pol for providing further information about the important 
issue of HCC recurrence after DAA therapy. We believe that the message 
may be stronger if the above points could be clarified. 
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